Skip to main content
S. 3991 117th Congress Senate

American Made Pharmaceuticals Act of 2022

Official title: A bill to direct the Secretary of Health and Human Services to conduct a demonstration program to test providing preferential treatment under the Medicare, Med… Show full official titleShow less

Official title: A bill to direct the Secretary of Health and Human Services to conduct a demonstration program to test providing preferential treatment under the Medicare, Medicaid, and CHIP programs for certain drugs and biologicals manufactured in the United States.

Introduced: April 5, 2022 Introduced by: Tina Smith Democratic · Minnesota See on congress.gov
Health Buy American requirementsChild healthCongressional oversightDrug therapy
More subjectsShow fewer subjects
Emergency medical services and trauma careHealth care costs and insuranceHealth technology, devices, suppliesInfectious and parasitic diseasesManufacturingMedicaidMedicarePoverty and welfare assistancePrescription drugsPublic contracts and procurement
Sign in to write a letter Sign in to watch
This bill died when the 117th Congress ended
It never became law before the 117th Congress (2021–2022) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 5, 2022
Read twice and referred to the Committee on Finance.
Apr 5, 2022
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action April 5, 2022

Read twice and referred to the Committee on Finance.

 Plain-English summary Congressional Research Service

American Made Pharmaceuticals Act of 2022

This bill requires the Centers for Medicare & Medicaid Services to conduct a demonstration program that gives preference to domestically manufactured drugs under Medicare, Medicaid, and the Children's Health Insurance Program (CHIP).

The program must be conducted in at least eight states and for at least seven years. Applicable drugs include critical drugs that are needed to respond to a public health emergency and that have a vulnerable global supply chain. Preference may take the form of reduced cost-sharing, preferential treatment on formularies, bonus payments, and other specified methods.

 Related & companion bills 1
  • HR 7400 Identical bill American Made Pharmaceuticals Act of 2022
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 1
All 1 Republican 1
R
Cotton, Tom
Arkansas · Apr 5, 2022
Cite this page click to expand
APA
U.S. Congress. (2026). S. 3991: American Made Pharmaceuticals Act of 2022. 117th Congress. Open America. https://openamerica.io/bill/117-S-3991/
MLA
"S. 3991: American Made Pharmaceuticals Act of 2022." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-S-3991/.
Bluebook (legal)
S. 3991, 117th Cong. (2026), https://openamerica.io/bill/117-S-3991/.
Markdown link
[S. 3991: American Made Pharmaceuticals Act of 2022](https://openamerica.io/bill/117-S-3991/)
Report a problem